ImmuCell Co. (NASDAQ:ICCC) Short Interest Update

ImmuCell Co. (NASDAQ:ICCC) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 11,700 shares, a growth of 37.6% from the September 15th total of 8,500 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 38,800 shares, the days-to-cover ratio is currently 0.3 days.

ImmuCell Stock Performance

ICCC traded up $0.06 during trading on Tuesday, hitting $3.63. The stock had a trading volume of 221 shares, compared to its average volume of 19,254. The company has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $4.30. ImmuCell has a 12 month low of $3.34 and a 12 month high of $5.59. The company has a current ratio of 2.37, a quick ratio of 0.77 and a debt-to-equity ratio of 0.42. The firm has a market cap of $28.36 million, a PE ratio of -7.00 and a beta of 0.56.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 16.35% and a negative net margin of 17.44%. The company had revenue of $5.47 million for the quarter.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.